tert-butyl N-(4-hydroxybenzenecarboximidoyl)carbamate | 76223-52-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: tert-butyl N-(4-hydroxybenzenecarboximidoyl)carbamate
• 英文别名: tert-butyl ((4-hydroxyphenyl)(imino)-methyl)carbamate；N-1,1-Dimethylethyl N-[(4-Hydroxyphenyl)iminomethyl]carbamic Acid Ester
• CAS: 76223-52-4
• 化学式: C₁₂H₁₆N₂O₃
• 分子量: 236.271
• InChiKey: GBFYWMIEBIBOII-UHFFFAOYSA-N

物化性质

• 熔点：
  >170oC (dec.)
• 密度：
  1.16±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（轻微、加热、超声处理）、DMSO（轻微）、甲醇（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl N-(4-hydroxybenzenecarboximidoyl)carbamate 在 氢溴酸 、 N,N'-二环己基碳二亚胺 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 N-benzoyl-DL-phenylalanine p-amidinophenylester p-toluenesulfonate
  参考文献：
  名称：

  Fujioka, Toshiyuki; Tanizawa, Kazutaka; Nakayama, Hitoshi, Chemical and pharmaceutical bulletin, 1980, vol. 28, # 6, p. 1899 - 1905

  摘要：

  DOI：
• 作为产物：
  描述：

  在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 tert-butyl N-(4-hydroxybenzenecarboximidoyl)carbamate
  参考文献：
  名称：

  CN115772132

  摘要：

  公开号：

文献信息

• [EN] AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS<br/>[FR] COMPOSÉS DE BÊTA-LACTAME À SUBSTITUTION AMIDINE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：AICURIS GMBH & CO KG

  公开号：WO2013110643A1

  公开（公告）日：2013-08-01

  The present invention relates to novel β-lactam compounds of formula (I), their preparation and use. In particular, this invention relates to novel β-lactam compounds which are amidine substituted monobactam derivatives useful as antimicrobial agents and their preparation.

  本发明涉及式(I)的新型β-内酰胺化合物，它们的制备和使用。特别是，本发明涉及作为抗菌剂有用的新型β-内酰胺化合物，即取代脒的单巴坦衍生物及其制备方法。
• GUANICIDE COMPOUND AND FUNGICIDE
  申请人：Nippon Soda Co., Ltd.

  公开号：US20180146677A1

  公开（公告）日：2018-05-31

  A novel guanidine compound having excellent fungicidal activity is represented by formula [I]. (In the formula, Y represents a divalent group represented by formula [II] (wherein each of R 7 -R 9 independently represents a hydrogen atom or the like) or the like; each of X and Z independently represents an unsubstituted or substituted alkylene group or the like; each of Q 1 and Q 2 independently represents a single bond or the like; each of A 1 and A 2 independently represents an unsubstituted or substituted divalent heterocyclic compound residue or the like; and each of R 1 -R 6 independently represents a hydrogen atom or the like.)

  一种具有优异杀菌活性的新型胍啉化合物由式[I]表示。（在该式中，Y代表由式[II]表示的二价基团（其中R7-R9中的每一个独立地表示氢原子或类似物）或类似物；X和Z中的每一个独立地表示未取代或取代的烷基基团或类似物；Q1和Q2中的每一个独立地表示单键或类似物；A1和A2中的每一个独立地表示未取代或取代的二价杂环化合物残基或类似物；R1-R6中的每一个独立地表示氢原子或类似物。）
• BENZOATE COMPOUND
  申请人：SCOHIA PHARMA, INC.

  公开号：US20210403420A1

  公开（公告）日：2021-12-30

  The present invention provides a benzoic acid ester compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. A compound represented by the formula (I) or a salt thereof has an enteropeptidase inhibitory effect and is useful as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like: [in the formula, each symbol is as defined in the specification].

  本发明提供了一种苯甲酸酯化合物，具有肠肽酶抑制作用，并将该化合物用作治疗或预防肥胖、糖尿病等疾病的药物。由式（I）表示的化合物或其盐具有肠肽酶抑制作用，并可用作治疗或预防肥胖、糖尿病等疾病的药物。【在公式中，每个符号如规范中定义】。
• Amidino derivatives and drugs containing the same as the active ingredient
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US06358960B1

  公开（公告）日：2002-03-19

  The novel amidino derivatives of the formula (I): wherein all the symbols are as in specification defined; have an inhibitory activity of a blood coagulation factor VIIa and are useful for treatment and/or prevention of several angiopathy caused by enhancing a coagulation activity, such as disseminated intravascular coagulation, coronary thrombosis, cerebral infarction, cerebral embolism, transient ischemic attack, cerebrovascular disorders, pulmonary vascular diseases, deep venous thrombosis, peripheral arterial obstruction, thrombosis after artificial vascular transplantation and artificial valve transplantation, post-operative thrombosis, reobstruction and restenosis after coronary artery bypass operation, reobstruction and restenosis after PTCA or PTCR, thrombosis by extracorporeal circulation and procoagulative diseases such as glomerlonephriitis.

  该式(I)的胍基衍生物小说：其中所有符号均如规范中所定义；具有抑制血凝血因子VIIa的活性，并可用于治疗和/或预防由增强凝血活性引起的多种血管病，如弥散性血管内凝血、冠状动脉血栓形成、脑梗死、脑栓塞、短暂性缺血发作、脑血管疾病、肺血管疾病、深静脉血栓形成、周围动脉阻塞、人工血管移植后血栓形成和人工瓣膜移植后血栓形成、术后血栓形成、冠状动脉旁路手术后再阻塞和再狭窄、PTCA或PTCR后再阻塞和再狭窄、体外循环引起的血栓形成以及像肾小球肾炎这样的促凝病。
• [EN] ANALOGUES OF PENTAMIDINE AND USES THEREFOR<br/>[FR] ANALOGUES DE LA PENTAMIDINE ET UTILISATIONS ASSOCIÉES
  申请人：AURANSA INC

  公开号：WO2020132636A1

  公开（公告）日：2020-06-25

  The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本公开提供一组芳香族（例如吡啶基，嘧啶基，吡嗪基或苯基）二胺类似物和药学上可接受的盐，用于治疗增生性疾病。增生性疾病可能包括实体癌或血液癌。本文介绍了使用类似物治疗各种癌症的组合物、合成方法以及治疗方法。本公开还提供至少含有一种化合物的药物配方，其中包含药学上可接受的载体、稀释剂或辅料。